China Biotech Services Holdings Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, the Group is expected to record a net profit of not less than HKD 100,000,000 for the 2021 Interim Period as compared to the net loss of approximately HKD 45,779,000 recorded for the corresponding period in 2020.